GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » Change In Payables And Accrued Expense

EYESW (Second Sight Medical Products) Change In Payables And Accrued Expense : $-1.34 Mil (TTM As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Second Sight Medical Products Change In Payables And Accrued Expense?

Second Sight Medical Products's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2022 was $0.05 Mil. It means Second Sight Medical Products's Accounts Payable & Accrued Expense increased by $0.05 Mil from Mar. 2022 to Jun. 2022 .

Second Sight Medical Products's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2021 was $-1.16 Mil. It means Second Sight Medical Products's Accounts Payable & Accrued Expense declined by $1.16 Mil from Dec. 2020 to Dec. 2021 .


Second Sight Medical Products Change In Payables And Accrued Expense Historical Data

The historical data trend for Second Sight Medical Products's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Second Sight Medical Products Change In Payables And Accrued Expense Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.79 -0.91 -1.43 -1.16

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 0.09 -1.62 0.14 0.05

Second Sight Medical Products Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Second Sight Medical Products Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Second Sight Medical Products Business Description

Traded in Other Exchanges
N/A
Address
13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.